More Evidence of Heart Risks from Bextra
Researchers Say Combining Bextra and Aspirin Could Increase Risk of Blood Clots
Jan. 18, 2005 -- Combining aspirin with the painkiller Bextra may magnify
the heart-related risks associated with Bextra and similar drugs.
Two new studies offer new clues about the role of Bextra in heart disease.
They suggest that combining Bextra with aspirin may increase the risk of blood
clots that could trigger a heart attack or stroke.
Last month, the FDA a which states that
Bextra should not be used in patients undergoing heart bypass surgery after a
clinical trial showed an increase in heart problems in bypass patients using
A similar drug, was removed from the market in
September 2004 because of an increase in heart attacks and stroke in patients
taking the drug for at least 18 months. A third, similar drug, was linked to heart attacks last
month as well.
Bextra is a member of a class of drugs called Cox-2 inhibitors. Like the
other Cox-2 inhibitors, Vioxx and Celebrex, it was designed to treat arthritis
and other painful conditions. Older drugs like ibuprofen and naproxen treat
pain and inflammation by blocking two enzymes, Cox-1 and Cox-2. However,
blocking the Cox-1 enzyme has been linked with side effects such as stomach
ulcers. Bextra and related drugs treat inflammation and pain by blocking only
Cox-2, thus decreasing the side effect of stomach ulcers.
In the studies, which appear in the Jan. 17 issue of Circulation:
Journal of the American Heart Association, researchers examined some
potential mechanisms behind the increase in heart problems associated with
In the first study, researchers studied the effects of Bextra and aspirin on
hardening of the arteries (atherosclerosis) in mice prone to the condition.
They found that low-dose aspirin slowed the development of in the mice, but it seemed
ineffective once the disease was established.
Adding a Cox-2 inhibitor didn't enhance the beneficial effects of aspirin.
Instead, researchers found the combination of Bextra and aspirin produced
potentially dangerous changes in the makeup of the plaque within the
"We were amazed," says researcher Karine Egan, PhD, of the
University of Pennsylvania, in a news release. "Addition of the Cox-2
inhibitor caused changes that, if they occurred in humans, would result in a
loss of stability of the plaque, making it more likely to rupture and activate
clotting, causing heart attack or stroke."
Researchers say aspirin protects against atherosclerosis by blocking Cox-1.
By adding a Cox-2 inhibitor, researchers say the beneficial effects of aspirin
may be lost by tipping the balance in favor of the Cox-1 enzyme. This could
increase the chance of developing dangerous blood clots that could lead to a
heart attack or stroke.
More Heart Problems for Bextra
In a related editorial, researchers presented the combined results of two
clinical studies of the drug Bextra and Dynastat.